In a prospective 4-year study, more of those with elevated cytokine levels had evidence of disease activity.
Although multiple sclerosis (MS) is often considered a disease of the white matter, appreciation is growing that pathology also directly affects the cortex. Meningeal inflammatory follicles may contribute to cortical injury through cytokines and subpial demyelination (NEJM JW Neurol Jun 2018 and Ann Neurol 2018; 83:739). To examine possible correlations between grey-matter inflammation and clinical disease progression, investigators evaluated inflammatory markers in the cerebrospinal fluid (CSF) in 99 patients with treatment-naive relapsing-remitting (RR) MS and followed them prospectively on MS treatment for 4 years.
During the study, 41 patients experienced some evidence of disease activity (relapse, new lesion, or worse disability score).…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)